Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
Dorte Lisbet Nielsen
, Michael Andersson, Claus Kamby
Department of Clinical Medicine
95
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Monoclonal Antibody
100%
Trastuzumab
100%
Protein Tyrosine Kinase Inhibitor
100%
Breast Cancer
100%
Metastatic Breast Cancer
40%
Gamma Urogastrone
20%
Capecitabine
20%
Blood-Brain Barrier
20%
Neoplasm
20%
Epidermal Growth Factor Receptor
20%
Overall Survival
20%
Disease Free Survival
20%
Tyrosine Kinase Receptor
20%
Chemotherapy
20%
Keyphrases
HER2-targeted Therapy
100%
Lapatinib
40%
Preoperative Setting
20%
Pathological Complete Response
20%
HER2-positive Early Breast Cancer
20%
Capecitabine
20%
Taxanes
20%
HER2-positive Metastatic Breast Cancer
20%
Vinorelbine
20%
Optimal Selection
20%